Dr. Liu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Highland Hospital
HCP 5 GI LAB
Oakland, CA 94602
Education & Training
University of Texas Southwestern Medical CenterFellowship, Gastroenterology, 2005 - 2009
University of MichiganResidency, Internal Medicine, 2001 - 2004
University of Texas Medical Branch School of MedicineClass of 2001
Certifications & Licensure
CA State Medical License 2012 - 2026
TX State Medical License 2006 - 2013
MI State Medical License 2001 - 2008- American Board of Internal Medicine Gastroenterology
Publications & Presentations
PubMed
- 5 citationsLong-term administration of intravenous Trappsol® Cyclo™ (HP-β-CD) results in clinical benefits and stabilization or slowing of disease progression in patients with Ni...Reena Sharma, Caroline Hastings, Orna Staretz-Chacham, Julian Raiman, Martin Paucar
Molecular Genetics and Metabolism Reports. 2023-09-01 - 19 citationsIntravenous 2-hydroxypropyl-β-cyclodextrin (Trappsol® Cyclo™) demonstrates biological activity and impacts cholesterol metabolism in the central nervous system and per...Caroline Hastings, Benny Liu, Bryan Hurst, Gerald F Cox, Sharon Hrynkow
Molecular Genetics and Metabolism. 2022-12-01 - 14 citationsRace/Ethnicity-specific Disparities in In-Hospital Mortality and Hospital Charges Among Inflammatory Bowel Disease-related Hospitalizations in the United States.Artin Galoosian, Mona Rezapour, Benny Liu, Taft Bhuket, Robert J. Wong
Journal of Clinical Gastroenterology. 2020-08-01
Press Mentions
Cyclo Therapeutics Announces Positive Efficacy Data from Extension Protocol with Trappsol® Cyclo™ in Patients with Niemann-Pick Disease Type CJanuary 5th, 2021
Cyclo Therapeutics Inc. Announces Positive Top Line Results from Phase I Trial and Interim Analysis of Phase I/II Trial Using Trappsol® Cyclo™ Intravenously to Treat Patients with Niemann-Pick Disease Type C1 (NPC1)May 20th, 2020- Last Patient Last Visit in Cyclo Therapeutics’ Phase I Trial in Niemann-Pick Type CFebruary 11th, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
